DUBLIN--(BUSINESS WIRE)--The "Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents), By Source, ...

DUBLIN--(BUSINESS WIRE)--The "Protein Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Protein Therapeutics was estimated at ...

AAA Bio’s recombinant proteins, offering high purity, consistency, and reliability for advancing research in drug ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "ADZYNMA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and ...

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

Today’s clinicians use recombinant therapeutic proteins, such as monoclonal antibodies, to treat many diseases, from autoimmune disorders to cancer and beyond. Nonetheless, sequence variants (SVs), ...

Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024 Composition of matter patent application filed on ...

SHIRLEY, NEW YORK, USA, July 1, 2024 /EINPresswire.com/ -- In the fast-paced world of pharmaceuticals, recombinant protein therapeutics, also known as biologics, play ...

-- Strategic research collaboration to advance MTx's recombinant polyclonal IgG technology -- Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the ...